HEL In Vivo Anti-Tumor Efficacy Assay

This assay is to provide HEL-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

HEL

Human

A new human erythroleukemia cell line has been established. This line, designated HEL, is capable of spontaneous and induced globin synthesis, producing mainly Gγ and Aγ chains. Embryonic chains (ε, ζ) and α chains are detectable in very small amounts; β chains are undetectable. This line provides a new model system for studying aspects of erythroid cell differentiation and differential globin gene expression.

Erythroleukemia

Oncology

In Vivo Anti-Tumor Efficacy Assay

HEL-cell based In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays